February 15th 2023
Data from the phase 3 ROMAN trial and the phase 2b GT-201 trial support the new drug application for avasopasem in radiotherapy-induced severe oral mucositis for those with head and neck cancer.
February 13th 2023
Radiotherapy De-Escalation Improves Toxicity in p16+ Oropharyngeal Squamous Cell CarcinomaFebruary 25th 2022
A presentation from the 2022 ASTRO Multidisciplinary Head and Neck Cancers Symposium showed a de-escalated radiotherapy dose to 54 Gy vs 70 Gy led to better measures of toxicity in those with p16+ oropharyngeal squamous cell carcinoma.
DART Meets Noninferiority PFS Benchmark in HPV-Related OPSCCFebruary 25th 2022
In a pre-planned pooled analysis of data from the MC1273 and MC1675 trials presented at the 2022 ASTRO Multidisciplinary Head and Neck Cancers Symposium, de-escalated adjuvant radiation therapy met criteria for efficacy in human papillomavirus–related oropharyngeal squamous cell carcinoma.
DART Yields Robust Survival Benefit vs Standard of Care in HPV-Associated Oropharyngeal Squamous Cell CarcinomaOctober 28th 2021
Patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma experienced good quality of life and promising survival benefit after being treated with de-escalated adjuvant radiation therapy.
Stereotactic Body Radiation Therapy Proves Relatively Safe to Use in OligometastasesOctober 27th 2021
Patients with up to 5 oligometastases tolerated stereotactic body radiation therapy well, with investigators identifying a relatively safe toxicity profile of grade 2 or higher adverse effects.
Primary Radiotherapy as De-Escalation Strategy Yields Efficacious Survival Outcomes in HPV-Associated Oropharyngeal Squamous Cell CarcinomaOctober 27th 2021
Patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma experienced efficacious survival benefits from treatment with primary radiotherapy.
Risk of Cardiotoxicity Not Increased With Radiation Therapy in Certain Patients With HER2-Positive Breast CancerOctober 27th 2021
Patients receiving trastuzumab for HER2-positive breast cancer on the phase 3 HERA trial did not have an increased risk of cardiotoxicity from radiation therapy.
Equivalent Toxicity, PROs Noted With Higher Radiation Dose Over Fewer Fractions After Breast Conserving SurgeryOctober 26th 2021
Patients who were treated with extreme hypofractionation after breast conserving surgery saw no increase in ill-treatment effects compared with those receiving moderate hypofractionation.
EBRT Underutilized as Bridging Therapy to Transplant for Hepatocellular Carcinoma Although Use Increased Over Past DecadeOctober 26th 2021
A retrospective review found that external-beam radiation therapy has been underutilized as a bridging therapy in patients with hepatocellular carcinoma seeking transplant, although its prevalence has increased over the past decade.
Hypofractionated Image-Guided Versus Conventionally Fractionated Radiotherapy Shows No Treatment Advantage in NSCLC With Poor Performance StatusAugust 29th 2021
The use of hypofractionated image-guide radiotherapy was not found to improve overall survival for patients with non–small cell lung cancer and poor performance status versus conventional fractionated radiation techniques.
Prophylactic Cranial Irradiation With Hippocampal Avoidance Preserves Cognitive Function During SCLC TreatmentAugust 22nd 2021
Hippocampal avoidance–prophylactic cranial irradiation was associated with better cognitive function preservation versus standard prophylactic cranial irradiation for small cell lung cancer.
Cardiovascular Risk May Increase With Radiotherapy Use During Treatment of Early-Stage Hodgkin LymphomaAugust 21st 2021
PET-negative patients who are treated with radiotherapy had a slightly increased absolute cardiovascular disease risk, although magnitude of these effects varied widely.
Clinical Trials in Progress: ROADS TrialAugust 8th 2021
Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) versus Surgically Targeted Radiation Therapy (STaRT) with GammaTile for Treatment of Newly Diagnosed Metastatic Brain Tumors (ROADS; NCT04365374)
Stereotactic Radiosurgery Safe and Effective for Brainstem MetastasesJune 2nd 2021
The results from a retrospective trial that found stereotactic radiosurgery produced comparable results for both brainstem metastases and nonbrainstem brain metastases suggest both groups of patients should be eligible for stereotactic radiosurgery clinical trials.
Multidisciplinary Team Developed to Promote Communication and Collaboration Among Radiation Oncology Care FacilityApril 21st 2021
The 2 pilot multidisciplinary care teams reported positive feedback with the collaboration, explaining that the meetings were valuable to the quality care of their patients.
ASTRO Survey of Radiation Oncologists Shows Treatment Delays, Health Disparities Resulting From COVID-19 PandemicMarch 31st 2021
Thomas J. Eichler, MD, FASTRO, presented data during a media briefing from surveys of radiation oncologists treating patients with cancer through the COVID-19 pandemic.
Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder CancerFebruary 25th 2021
Data published in The Lancet Oncology found that a hypofractionated radiation schedule of 55 Gy in 20 fractions is noninferior to a schedule of 64 Gy in 32 fractions for patients with this disease.
Stereotactic Ablative Body Radiotherapy Improved Survival, Maintained Safety for Oligometastatic CancersFebruary 15th 2021
A recent trial investigating the potential for stereotactic ablative body radiotherapy to treat patients with extracranial oligometastatic cancer found improved survival and a manageable safety profile.
Adjuvant Radiotherapy Linked With Survival Benefit After Distal Cholangiocarcinoma ResectionFebruary 8th 2021
Data published in Cancer found adjuvant radiotherapy after distal cholangiocarcinoma resection was associated with a survival benefit for patients, regardless of margin or nodal status.
Sexual Dysfunction Not Well Addressed in Female Cancer SurvivorsNovember 4th 2020
“Sexual dysfunction is an unfortunately common side effect of cancer treatment, and there appears to be a large gender disparity in how physicians discuss sexual health with their patients,” said lead study author James Taylor, MD, MPH.
SBRT Appears to be Superior to CRT for Controlling Pain Related to Spinal MetastasesOctober 31st 2020
Stereotactic body radiotherapy may be superior to conventional palliative radiotherapy in improving the complete response rate for pain related to spinal metastases at 3- and 6-months post-radiation.
Study Suggests Stereotactic Radiosurgery Become Standard of Care for Patients with 4+ Brain MetastasesOctober 31st 2020
When compared with whole brain radiation therapy, researchers discovered highly focused radiation therapy led to less cognitive decline while simultaneously delivering equivalent overall survival rates.